Monitoring Bevacizumab-Induced Tumor Vascular Normalization by Intravoxel Incoherent Motion Diffusion-Weighted MRI

被引:11
作者
Li, Bo [1 ,2 ]
Xu, Dan [1 ]
Zhou, Jie [1 ]
Wang, Shou-Chao [1 ]
Cai, Yu-Xiang [3 ]
Li, Huan [1 ]
Xu, Hai-Bo [1 ]
机构
[1] Wuhan Univ, Dept Radiol, Zhongnan Hosp, Wuhan, Peoples R China
[2] Yangtze Univ, Affiliated Hosp 1, Jingzhou, Peoples R China
[3] Wuhan Univ, Zhongnan Hosp, Dept Pathol, Wuhan, Peoples R China
基金
中国国家自然科学基金;
关键词
intravoxel incoherent motion; diffusion-weighted imaging; microvessel density; pericyte coverage; angiogenesis; PERFUSION; CANCER; ANGIOGENESIS; INHIBITION; THERAPY; IVIM;
D O I
10.1002/jmri.28012
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background Accurate monitoring of tumor blood vessel normalization progression is beneficial to accurate treatment of patients. At present, there is a lack of safe and noninvasive monitoring methods. Purpose To serial monitor the vascular normalization time window of tumor antiangiogenesis treatment through intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) and histopathological methods. Study Type Exploratory animal study. Population Sixty rat C6 glioma models were randomly and equally divided into the control groups (N = 30) and bevacizumab treatment groups (N = 30). Twenty-five for magnetic resonance imaging (MRI) and five for electron microscope testing in each group. Field Strength/Sequence T1-weighted imaging (T1WI), T2WI with a fast spin echo sequence and IVIM-DWI with a spin-echo echo-planar imaging sequence at 3 T. Assessment IVIM-DWI quantitative parameters (f, D, D*, and fD*) were obtained on days 0, 2, 4, 6, and 8 after bevacizumab treatment. After MRI, the microvessel density (MVD), pericyte coverage, and hypoxia-inducible factor-1 alpha (HIF-1 alpha) were assessed. Electron microscope observation was performed at each time point. Statistical Tests One-way analysis of variance and Student's t-tests were used to compare differences within and between groups. Spearman's correlation coefficient (r) assess the correlation between IVIM and pathological parameters. The intragroup correlation coefficient was determined to assess the repeatability of each IVIM parameter. Results The IVIM-DWI perfusion parameters (f and fD*) of the treated group were higher than the control group on days 2 and 4. Compared to the control group, MVD decreased on days 2 and pericyte coverage increased on days 4 in the treatment group. Electron microscopy showed that the tight junctions of the treatment group were prolonged on days 2-4. In the control group, f had the highest correlation with MVD (r = 0.689). In the treated group, f had a good correlation with pericyte coverage (r = 0.557), HIF-1 alpha had a moderately positive correlation with f (r = 0.480) and fD*(r = 0.447). Data Conclusion The vascular normalization time window of bevacizumab treatment of glioma was days 2-4 after antiangiogenesis treatment, which could be monitored noninvasively by IVIM-DWI. Evidence Level 2 Technical Efficacy Stage 3
引用
收藏
页码:427 / 439
页数:13
相关论文
共 36 条
[1]   Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases [J].
Carmeliet, Peter ;
Jain, Rakesh K. .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (06) :417-427
[2]   Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response [J].
Cesca, Marta ;
Morosi, Lavinia ;
Berndt, Alexander ;
Nerini, Ilaria Fuso ;
Frapolli, Roberta ;
Richter, Petra ;
Decio, Alessandra ;
Dirsch, Olaf ;
Micotti, Edoardo ;
Giordano, Silvia ;
D'Incalci, Maurizio ;
Davoli, Enrico ;
Zucchetti, Massimo ;
Giavazzi, Raffaella .
MOLECULAR CANCER THERAPEUTICS, 2016, 15 (01) :125-135
[3]   A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer [J].
Chen, Bang-Bin ;
Lu, Yen-Shen ;
Lin, Ching-Hung ;
Chen, Wei-Wu ;
Wu, Pei-Fang ;
Hsu, Chao-Yu ;
Yu, Chih-Wei ;
Wei, Shwu-Yuan ;
Cheng, Ann-Lii ;
Shih, Tiffany Ting-Fang .
BMC CANCER, 2016, 16
[4]   Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse [J].
Cui, Yanfen ;
Zhang, Caiyuan ;
Li, Xiaoming ;
Liu, Huanhuan ;
Yin, Bing ;
Xu, Tianyong ;
Zhang, Yong ;
Wang, Dengbin .
SCIENTIFIC REPORTS, 2015, 5
[6]   Measuring brain perfusion with intravoxel incoherent motion (IVIM): Initial clinical experience [J].
Federau, Christian ;
O'Brien, Kieran ;
Meuli, Reto ;
Hagmann, Patric ;
Maeder, Philippe .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2014, 39 (03) :624-632
[7]   Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure [J].
Ferretti, S ;
Allegrini, PR ;
O'Reilly, T ;
Schnell, C ;
Stumm, M ;
Wartmann, M ;
Wood, J ;
McSheehy, PMJ .
CLINICAL CANCER RESEARCH, 2005, 11 (21) :7773-7784
[8]   Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook [J].
Garcia, Josep ;
Hurwitz, Herbert, I ;
Sandler, Alan B. ;
Miles, David ;
Coleman, Robert L. ;
Deurloo, Regula ;
Chinot, Olivier L. .
CANCER TREATMENT REVIEWS, 2020, 86
[9]   Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs [J].
Hutchinson, L. G. ;
Mueller, H-J ;
Gaffney, E. A. ;
Maini, P. K. ;
Wagg, J. ;
Phipps, A. ;
Boetsch, C. ;
Byrne, H. M. ;
Ribba, B. .
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2016, 5 (11) :636-645
[10]   Clinical Intravoxel Incoherent Motion and Diffusion MR Imaging: Past, Present, and Future [J].
Iima, Mami ;
Le Bihan, Denis .
RADIOLOGY, 2016, 278 (01) :13-32